Your SlideShare is downloading. ×
0
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Dynamic Epidemiology of Streptococcus pneumoniae- Joshua Metlay MD PhD

688

Published on

Eastern PA Branch-ASM, 41st Annual Symposium, Nov 17, 2011

Eastern PA Branch-ASM, 41st Annual Symposium, Nov 17, 2011

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
688
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. The Dynamic Epidemiology of Streptococcus pneumoniae. Joshua P. Metlay, MD, PhD Division of General Internal Medicine University of Pennsylvania Presented at the 41st Annual Symposium“Global Movement of Infectious Pathogens and Improved Laboratory Detection” Eastern PA Branch-American Society for Microbiology November 17, 2011 Thomas Jefferson University, Philadelphia
  • 2. Outline• Introduction to pneumococcal disease• Secular trends –Antimicrobial drug resistance (macrolides) –Serotype replacement• Geographic patterns
  • 3. Survival from pneumococcal bacteremia 1952-1962
  • 4. Penicillin Resistance in S. pneumoniae United States 1979-2000 Sentinel ABCs1979-1994: CDC Sentinel Surveillance Network1995-2002: CDC Active Bacterial Core Surveillance (ABCs) /Emerging Infections Program
  • 5. The Delaware Valley Hospital Network• Hospital based reporting of cases of pneumococcal bacteremia• Established in 2001• Centralized susceptibility testing• 48 hospitals in the 5 county region of Southeastern Pennsylvania• 3.7 million population• 400 annual cases
  • 6. Participating hospitals in the Delaware Valley Emerging Infectious Diseases 2001
  • 7. Risk Factors for Pneumococcal BacteremiaCharacteristic Cases per 100,000 95% CIAge 18-49 8.3 7.5 – 9.2 50-64 15.9 14.4 – 17.6 65-79 26.4 26.4 – 29.5 80+ 59.4 52.7 – 67Race White 13.7 12.9 – 14.7 African American 26.4 24.2 – 28.9
  • 8. Time Trends
  • 9. Pneumococcal Conjugate Vaccine• Seven valent conjugate vaccine licensed in February 2000• 4, 6B, 9V, 14, 18C, 19F, 23F• Widespread use by June 2000.• 2,4, 6, 13-15 month immunization schedule• Efficacy for otitis media, invasive disease, pneumonia.• Reduction in carriage of vaccine serotypes
  • 10. Temporal trends in risk of invasive pneumococcal disease: children
  • 11. Temporal trends in risk of invasive pneumococcal disease: adults
  • 12. What is Herd Immunity? Picture courtesy of Dr. C. Whitney
  • 13. Early Successes with Vaccination Rate of VT IPD per 100,000 population Direct effect: 94% decrease Indirect effect: 65% decrease CDC. MMWR 2005; 54: 893-7.
  • 14. Vaccination of children reduces risk of disease in adults 100 Cases Controls 80 60% 40 20 0 Any child vaccinated Youngest child vaccinated Vaccine. 2006
  • 15. Archives of IM 2010
  • 16. CLSI Breakpoints 2011Drug MIC (ug/mL) Interpretive Standard S I RPenicillin (Meningitis) ≤ 0.06 0.12-1 ≥2Penicillin (Non-meningitis) ≤2 4 ≥8Erythromycin ≤0.25 0.5 ≥1
  • 17. [1] Macrolide Resistance Genotypes Genotype Year 2001-2 2002-3 2003-4 2004-5 2005-6 2006-7 2007-8 p-value (n=55) (n=41) (n =42) (n=57) (n=84) (n=93) (=89) mefA+ermB- 72.7% 70.7% 52.4% 50.9% 40.5% 44.1% 34.8% <.0001 mefA-ermB+ 20.0% 26.8% 26.2% 36.8% 40.5% 31.2% 46.1% .01 ermB+mefA 1.8% 0.0% 9.5% 10.5% 17.9% 23.7% 19.1% <.0001 + 23S rRNA 3.6% 2.4% 7.1% 0.0% 1.2% 1.1% 1.1% .17 (A2059G)
  • 18. Emerging Macrolide Resistance
  • 19. PCV-13• Introduction of PCV-13 in 2000• Coverage of PCV-7 serotypes: –4,6B,9V,14,18C,19F,23F• Additional serotypes: –1,3,5,6A,7F,19A
  • 20. Pediatric Carriage of Pneumococcal Serotypes 2008-2010 20 18 16 6C 14 35B 19A% of isolates 12 11A 15C 10 23B 23A 8 15A 21 6 15B like 16F 4 22F 15B 2 0 2008 2009 2010 YEAR
  • 21. Spatial Trends
  • 22. Tobler’s First Law of Geography“Everything is related to everythingelse, but near things are more relatedthan distant things’’
  • 23. Pneumococcal Case Distribution
  • 24. Disease risk varies by neighborhood
  • 25. Significant hot spots exist
  • 26. Why are there clusters of disease?• Small area outbreaks from highly virulent clones – Pathogen Hypothesis• Neighborhood level exposures influence risk of transmission – Vector Hypothesis• Heterogenous population distribution – Host Hypothesis
  • 27. PFGE Analysis of Pneumo Isolates
  • 28. Genetic clustering vs. geographic clustering
  • 29. Children as Vectors Huang CID 2005
  • 30. Child Exposure is Associated with Reduced Risk of DiseaseCharacteristic Cases per 100,000 95% CI# of children inhome 0 21.5 20.3 – 22.8 1 8.3 6.8 – 9.9 2+ 3.3 2.6 – 4.2 Archives of Internal Med 2010
  • 31. Key Points• Overall risk of pneumococcal disease has declined but new serotypes are emerging• Emerging serotypes are primarily multidrug resistance, reflecting selection of MDR clones and expansion of previously low prevalence serotypes• Variation in disease risk likely reflects host factors, but vector and pathogen factors are rapidly changing in pneumococcal disease.
  • 32. Thanks• Robert Austrian • Marshall Joffe• Lou Bell • Ebb Lautenbach• Catherine Berjohn • Yimei Li• Charlie Branas • Zhenying Liu• Linda Crossette • Russell Localio• Chris Czaja • Mat Macdonald• Paul Edelstein • Irv Nachamkin• Kristen Feemster • Samir Shah• Neil Fishman • Justine Shults• James Flory • Tony Smith

×